Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Lantheus Holdings, Inc

LNTH

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

Last trade $101.77
Day change +$0.05 (+0.05%)
Day range $101.11 – $102.05
Volume 302,038
Market cap $6.65B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.65B
Price / earnings
24.65×
Price / book
4.91×
Price / sales
4.26×
EV / sales
4.19×
EV / EBITDA
17.13×

Profitability

Earnings per share
$4.13
Return on assets
10.99%
Return on equity
19.91%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.42×
Current ratio
3.25×
Quick ratio
3.06×
Cash ratio
1.98×

Cash flow

Price / cash flow
16.25×
Price / free cash flow
16.92×
Free cash flow
$393.09M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LNTH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$389.91M$388.18M$377.33M$406.79M$384.01M$378.05M$372.76M$391.11M
Cost of revenue$146.5M$146.33M$146.41M$165.91M$161.65M$137.03M$135.06M$142.57M
Gross profit$243.41M$241.86M$230.92M$240.88M$222.37M$241.01M$237.7M$248.55M
Selling, general and administrative$118.44M$103.44M$110.22M$116.21M$130.73M$107.56M$99.32M$101.51M
Research and development$92.76M$38.2M$39.38M$47.48M$48.03M$45.49M$36.31M$35.33M
Total operating expenses$211.21M$141.64M$149.6M$163.69M$178.75M$153.05M$135.63M$136.83M
Operating income$32.21M$100.22M$81.33M$77.18M$43.62M$87.97M$102.07M$111.71M
Interest expense-$4.94M-$4.92M-$4.86M-$5.08M-$4.95M-$4.92M-$4.8M-$5.05M
Income before taxes$21.78M$93.83M$156.41M$70.37M$42.38M$104.52M$96.53M-$783K
Income taxes-$594K$18.8M$37.99M$16.28M$14.61M$25.76M$23.58M$11.01M
Net income$22.37M$75.03M$118.42M$54.09M$27.77M$78.76M$72.95M-$11.79M
Net income attributable to common shareholders$22.37M$75.03M$118.42M$54.09M$27.77M$78.76M$72.95M-$11.79M
EBITDA$55.1M$122.8M$104.01M$100.02M$64.02M$101.2M$115.69M$129M
Basic earnings per share$0.34$1.15$1.83$0.83$0.41$1.15$1.06-$0.17
Diluted earnings per share$0.33$1.11$1.80$0.84$0.41$1.12$1.02-$0.16

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

GlobeNewswire Inc.

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

Curium announced FDA approval of BEXLUTRY, a radioligand therapy for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval marks Curium's first radioligand therapy and represents expansion into oncology therapeutics. The company also announced acquisitions of Abscint SA and a definitive merger agreement with Lantheus to create a global radiopharmaceutical leader.

GlobeNewswire Inc.

Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - SNS Insider

The radioligand therapy market is projected to grow at an 18.2% CAGR through 2035, driven by increased prostate cancer and neuroendocrine tumor cases, FDA approvals for PSMA-targeted therapies like Pluvicto, and expanded isotope production capacity. North America dominates with 80.5% market share, while Asia-Pacific is the fastest-growing region at 21.5% CAGR.

GlobeNewswire Inc.

Curium Announces Definitive Agreement to Merge with Lantheus

Curium US has agreed to acquire Lantheus Holdings for $102.50 per share in cash at closing, plus up to $12.00 per share in contingent value rights, valuing the transaction at up to $8.0 billion. The combination aims to create a comprehensive radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries, with the deal expected to close in the first half of 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.